Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Novo Nordisk and Glooko Partner to Improve Diabetes Management

XTALKS VITALS NEWS

Blood Glucose

The pharmaceutical company will apply Glooko’s FDA-cleared, HIPPA-compliant platform to develop an app designed to help diabetic patients improve their blood glucose control.

Share this!

January 10, 2017 | by Sarah Hand, M.Sc.

Danish diabetes drugmaker, Novo Nordisk, has partnered with mHealth company, Glooko, to develop patient-centric apps for better diabetes management. The pharmaceutical company will apply Glooko’s FDA-cleared, HIPPA-compliant platform to develop an app designed to help diabetic patients improve their blood glucose control.

Novo Nordisk is the world’s leading supplier of diabetes medications. The partnership will provide California-based Glooko with access to Novo Nordisk’s customer information, along with its diabetes-based educational resources.

“We will add that [content] to our mobile platform,” Glooko CEO Rick Altinger told MedCity News. “The vision is to leverage data to drive better and faster decisions to help patients and their caregivers get to better outcomes.”

Glooko’s diabetes management platform has allowed the company to collect patient data on about one million diabetic patients globally. In addition, over 4,800 health systems have adopted the technology for disease management and remote patient monitoring.



According to Altinger, Glooko not only helps patients track all of the variables that affect their diabetes management, but it also offers companies a way to add diabetes information into electronic health records (EHR). “Diabetes is a data-driven disease, said Altinger. “Health systems can pull in data from Glooko, into workflows and integrate with EHRs if they want.”

Aside from this most recent deal with Novo Nordisk, Glooko has already established deals with diabetes medical device makers, including Roche. As the agreement with Novo Nordisk is nonexclusive, the company’s partnership with IBM Watson Health will likely also come into play.

“We are excited to partner with Glooko and to take another step towards delivering digital health offerings that help people with diabetes to improve their blood glucose control,” said Christian Kanstrup, Novo Nordisk’s senior vice president for strategy, access and marketing. “Working in partnerships will furthermore enhance our ability to demonstrate the real-world value of our portfolio of diabetes treatments.”

While it’s unclear exactly what products will come out of the partnership, Glooko has said that personalized support for diabetic patients and their caregivers is the major goal. The first digital health offering could be made available before the end of this year.


Keywords: Diabetes, mHealth, Disease Management


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.